CGAS and chronic kidney disease: Moreover, inhibition of ornithine decarboxylase (OCD1) – which is transactivated by the cGAS-STING pathway and an activator of ATP-producing metabolic pathways which promote LVH – using difluoromethylornithine (DFMO) also led to inhibition of CKD-induced LVH.